Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers
- PMID: 35309737
- PMCID: PMC8927991
- DOI: 10.1016/j.jtauto.2022.100151
Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers
Abstract
Clear guidance is needed in the development and implementation of laboratory biomarkers in medicine. So far, no standardized phased approach is established that would pilot researchers and clinicians in this process. This leads to often incompletely validated biomarkers, which can bear the consequence of wrong applications, misinterpretation and inadequate management in the clinical context. In this conceptual article, we describe a stepwise approach to develop and comprehensively validate laboratory biomarkers. We will delineate basic steps including technical performance, pre-analytical issues, and biological variation, as well as advanced aspects of biomarker utility comprising interpretability, diagnostic and prognostic accuracy, and health-care outcomes. These aspects will be illustrated by using well-known examples from the field of immunology. The application of this conceptual framework will guide researchers in conducting meaningful projects to develop and evaluate biomarkers for the use in clinical practice. Furthermore, clinicians will be able to adequately interpret pre-clinical and clinical diagnostic literature and rationally apply biomarkers in clinical practice. Improvement in the implementation and application of biomarkers might relevantly change the management and outcomes of our patients for the better.
Keywords: Biomarkers; Diagnostic techniques and procedures; Diagnostic test approval; Laboratories / standards; Predictive value of tests; Sensitivity and specificity.
© 2022 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Translating Laboratory Tests into Clinical Practice: A Conceptual Framework.Hamostaseologie. 2020 Nov;40(4):420-429. doi: 10.1055/a-1227-8008. Epub 2020 Sep 22. Hamostaseologie. 2020. PMID: 32961575
-
Method/ology of Phases of Biomarker Discovery.Hosp Pediatr. 2023 Jul 1;13(7):e181-e185. doi: 10.1542/hpeds.2022-007012. Hosp Pediatr. 2023. PMID: 37317806 Free PMC article.
-
[Evidence-based laboratory medicine].Orv Hetil. 2003 May 4;144(18):869-76. Orv Hetil. 2003. PMID: 12785240 Review. Hungarian.
-
High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification.Crit Rev Clin Lab Sci. 2017 May;54(3):143-172. doi: 10.1080/10408363.2017.1285268. Epub 2017 May 1. Crit Rev Clin Lab Sci. 2017. PMID: 28457177 Review.
References
-
- Moons K.G. Criteria for scientific evaluation of novel markers: a perspective. Clin. Chem. 2010;56(4):537–541. - PubMed
-
- Nagler M. Translating laboratory tests into clinical practice: a conceptual framework. Hämostaseologie. 2020;40(4):420–429. - PubMed
-
- Lijmer J.G., Leeflang M., Bossuyt P.M. Proposals for a phased evaluation of medical tests. Med. Decis. Making. 2009;29(5):E13–E21. - PubMed
-
- Price C.P., Christenson R.H. second ed. AACC Press; Washington, DC: 2007. Evidence-based Laboratory Medicine: Principles, Practice, and Outcomes.